Prothena Corporation plc (PRTA)
NASDAQ • Healthcare
Last close at September 9, 2026 at 20:00 UTC
Metrics Over Time
Where the Money Goes
Q2 2026Fundamentals & Financials
TTM is calculated as the sum of the four most recently completed quarters. This is a standard approach when monthly or real-time data is not available.
Income Statement
Balance Sheet
Financial Highlights
Dividends History
Split History
Earnings
Nov 5
in 56 daysQ4 2026% — EPS deviation from the forecast (beat / miss); quarters without a forecast show the reported EPS
About Prothena Corporation plc
Prothena Corporation plc is a NASDAQ-listed biotechnology company focused on discovering and developing novel therapies for diseases caused by protein dysregulation. Founded in 2012 and based in Dublin, Prothena operates as a clinical-stage drug developer centered on neurodegenerative and other protein-misfolding disorders.
Today's Snapshot
Yesterday PRTA fell 2.5% to 9.30. Prothena management will discuss the company at an H.C. Wainwright investor conference.
Trading Volume
Below 10d avg (333.1K)
294.5K
vs S&P 500 Today
Underperforming Market
-2.04%
Updated: September 10, 2026 at 12:03 UTC
Technical Indicators
All signalsHide signals
- EMA (5 indicators)$9.18 - $9.46Sell
- RSI (14)51.08Neutral
- Stochastic %K (14, 3, 3)72.85Neutral
- MACD Level (12, 26)0.17Buy
Peers & Related Assets
Get premium market insights delivered directly to your inbox.